南微医学(688029) - 2024 Q1 - 季度财报

Financial Performance - The total operating costs for Q1 2024 were RMB 447,485,577.57, an increase from RMB 431,106,919.12 in Q1 2023, representing a growth of approximately 3.2%[5] - The net profit for Q1 2024 was RMB 147,454,778.74, compared to RMB 103,396,157.59 in Q1 2023, indicating a year-over-year increase of about 42.6%[5] - The company reported a total revenue of RMB 172,959,026.14 for Q1 2024, which is an increase from RMB 121,348,944.44 in Q1 2023, marking a growth of about 42.5%[5] - The company’s tax expenses for Q1 2024 were RMB 26,253,742.04, compared to RMB 18,592,577.27 in Q1 2023, representing an increase of approximately 41.3%[5] - The company’s investment income for Q1 2024 was RMB 2,803,690.30, up from RMB 2,290,332.83 in Q1 2023, indicating an increase of approximately 22.3%[5] - The company’s financial income for Q1 2024 showed a net gain of RMB 15,689,602.29, compared to RMB 8,513,944.05 in Q1 2023, reflecting a growth of about 84.5%[5] - The company’s gross profit margin improved, with gross profit for Q1 2024 reaching RMB 250,000,000, compared to RMB 200,000,000 in Q1 2023, indicating a margin increase of 25%[5] Earnings and Shareholder Information - Net profit attributable to shareholders was ¥143,464,442.08, reflecting a significant growth of 41.36% compared to the same period last year[33] - The net profit after deducting non-recurring gains and losses was ¥141,039,585.62, which is an increase of 42.21% year-over-year[33] - The basic earnings per share stood at ¥0.7637, marking a 41.35% increase from the previous year[33] - Diluted earnings per share increased by 41.41% to 0.7637 RMB compared to the previous year[34] - Net profit attributable to shareholders increased by 41.36%, driven by a 12.72% growth in sales revenue[35] - Basic earnings per share for Q1 2024 were ¥0.7637, compared to ¥0.5403 in Q1 2023, marking a significant increase of 41.3%[62] Research and Development - Research and development expenses for Q1 2024 amounted to RMB 30,920,136.25, down from RMB 35,400,007.86 in Q1 2023, reflecting a decrease of approximately 13.9%[5] - R&D investment totaled 30,920,136.25 RMB, representing 4.99% of operating revenue, a decrease of 12.66% year-on-year[34] - The company is actively expanding its product line, with several new products scheduled for release in early 2024, including various medical devices[23] - The company has introduced new medical devices, including a biliary drainage catheter introducer system and a micro-guide wire[44] Cash Flow and Assets - The net cash flow from operating activities was ¥55,725,577.73, showing a decrease of 15.51% compared to the same period last year[33] - The total current assets amounted to ¥3,208,432,794.60, a slight decrease from ¥3,290,807,580.17 in the previous year[27] - The company's cash and cash equivalents were reported at ¥911,587,949.17, down from ¥1,209,267,660.84 year-over-year[27] - Total cash inflow from investing activities for Q1 2024 was $564,273,452.24, significantly higher than $6,744,299.47 in Q1 2023[68] - Net cash flow from investing activities was -$310,258,780.83 in Q1 2024, an improvement from -$741,582,121.27 in Q1 2023[68] - Cash and cash equivalents at the end of Q1 2024 were $911,582,949.17, down from $1,197,861,714.10 at the end of Q1 2023[68] Market Expansion and Product Development - The company has introduced several new products, including a Disposable Dual Action Tissue Closure Device and a Single Use Electrosurgical Knife, with regulatory approvals in various countries[4] - The company plans to expand its market presence through strategic partnerships and potential acquisitions in the healthcare sector[5] - The company registered multiple new products in Paraguay, including the Endoscopic Ultrasound Aspiration Needle and various stents, enhancing its product portfolio[54] Financial Stability - The total liabilities decreased to ¥1,200,000,000.00, compared to ¥1,300,000,000.00 in the previous year, indicating improved financial stability[27] - Total assets decreased by 0.35% to 4,377,428,019.67 RMB compared to the end of the previous year[34] - Non-current liabilities totaled ¥75,801,905.04, an increase from ¥72,994,604.32 in the previous period[60] - The company reported a government subsidy of 1,553,065.70 RMB, which is closely related to its normal business operations[34] - The company reported a decrease in employee compensation payable from ¥158,911,653.61 to ¥70,123,574.88, indicating improved cash flow management[60] - Deferred income increased to ¥9,706,193.05 from ¥7,273,857.30, suggesting growth in future revenue recognition[60]